ITRM20020049A1 - Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro. - Google Patents
Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.Info
- Publication number
- ITRM20020049A1 ITRM20020049A1 IT2002RM000049A ITRM20020049A ITRM20020049A1 IT RM20020049 A1 ITRM20020049 A1 IT RM20020049A1 IT 2002RM000049 A IT2002RM000049 A IT 2002RM000049A IT RM20020049 A ITRM20020049 A IT RM20020049A IT RM20020049 A1 ITRM20020049 A1 IT RM20020049A1
- Authority
- IT
- Italy
- Prior art keywords
- directed against
- neutralizing
- glycrotein
- monoclonal antibodies
- human monoclonal
- Prior art date
Links
- 230000003472 neutralizing effect Effects 0.000 title abstract 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 title 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 title 1
- 238000000338 in vitro Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
- C07K16/109—Hepatitis C virus; Hepatitis G virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2002RM000049A ITRM20020049A1 (it) | 2002-01-30 | 2002-01-30 | Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro. |
KR1020047011208A KR101002791B1 (ko) | 2002-01-30 | 2003-01-29 | Hcv e2 당단백질을 표적하고 시험관내 중화 활성을보유하는 사람 단클론항체 fab 단편 |
CNA038030926A CN1856508A (zh) | 2002-01-30 | 2003-01-29 | 针对HCV E2糖蛋白并赋予了体外中和活性的人单克隆抗体Fab片段 |
JP2003564093A JP4287280B2 (ja) | 2002-01-30 | 2003-01-29 | HCVE2グリコプロテインに対して向けられ、invitro中和活性を有するヒトモノクローナル抗体Fab断片 |
EA200401081A EA009861B1 (ru) | 2002-01-30 | 2003-01-29 | Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro |
CA2474801A CA2474801C (en) | 2002-01-30 | 2003-01-29 | Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity |
AU2003208000A AU2003208000B2 (en) | 2002-01-30 | 2003-01-29 | Human monoclonal antibody fab fragments directed against HCV E2 glycoprotein and endowed with in vitro neutralizing activity |
AT03705004T ATE407147T1 (de) | 2002-01-30 | 2003-01-29 | Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein |
PCT/IT2003/000032 WO2003064473A2 (en) | 2002-01-30 | 2003-01-29 | Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity |
EP03705004A EP1476468B9 (en) | 2002-01-30 | 2003-01-29 | Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity |
RU2004126238/13A RU2004126238A (ru) | 2002-01-30 | 2003-01-29 | Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro |
ES03705004T ES2314179T3 (es) | 2002-01-30 | 2003-01-29 | Fragmentos fab de anticuerpo monoclonal humano dirigidos contra la gucoproteina e2 del vhc y que estan dotados de actividad neutralizante in vitro. |
NZ534922A NZ534922A (en) | 2002-01-30 | 2003-01-29 | Human monoclonal antibody fab fragments directed against HCV E2 glycoprotein and endowed with in vitro neutralizing activity |
US10/502,307 US20050084845A1 (en) | 2002-01-30 | 2003-01-29 | Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity |
DE60323333T DE60323333D1 (de) | 2002-01-30 | 2003-01-29 | Fab-fragmente humaner monoklonaler antikörper mit protein |
DK03705004T DK1476468T3 (da) | 2002-01-30 | 2003-01-29 | Fab-fragmenter af humant monoklonalt antistof rettet mod HCV E2-glycoprotein og med in vitro-neutraliserende aktivitet |
ZA200406187A ZA200406187B (en) | 2002-01-30 | 2004-08-03 | Human monoclonal antibody fab fragments directed against HCV E2 glycoprotein and endowed with in vitro neutralizing activity |
US12/128,344 US7727529B2 (en) | 2002-01-30 | 2008-05-28 | Human monoclonal antibody Fab fragments directed against HCV E2 glycoprotein and endowed with in vitro neutralizing activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2002RM000049A ITRM20020049A1 (it) | 2002-01-30 | 2002-01-30 | Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro. |
Publications (2)
Publication Number | Publication Date |
---|---|
ITRM20020049A0 ITRM20020049A0 (it) | 2002-01-30 |
ITRM20020049A1 true ITRM20020049A1 (it) | 2003-07-30 |
Family
ID=11456013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IT2002RM000049A ITRM20020049A1 (it) | 2002-01-30 | 2002-01-30 | Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro. |
Country Status (17)
Country | Link |
---|---|
US (2) | US20050084845A1 (it) |
EP (1) | EP1476468B9 (it) |
JP (1) | JP4287280B2 (it) |
KR (1) | KR101002791B1 (it) |
CN (1) | CN1856508A (it) |
AT (1) | ATE407147T1 (it) |
AU (1) | AU2003208000B2 (it) |
CA (1) | CA2474801C (it) |
DE (1) | DE60323333D1 (it) |
DK (1) | DK1476468T3 (it) |
EA (1) | EA009861B1 (it) |
ES (1) | ES2314179T3 (it) |
IT (1) | ITRM20020049A1 (it) |
NZ (1) | NZ534922A (it) |
RU (1) | RU2004126238A (it) |
WO (1) | WO2003064473A2 (it) |
ZA (1) | ZA200406187B (it) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7611709B2 (en) * | 2004-05-10 | 2009-11-03 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives |
US7723306B2 (en) | 2004-05-10 | 2010-05-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation |
US7727962B2 (en) | 2004-05-10 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder comprising new compositions of oligosaccharides and methods for their preparation |
ITTO20070066A1 (it) | 2007-01-30 | 2008-07-31 | Pomona Biotechnologies Llc | Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv |
JP2010519916A (ja) * | 2007-03-06 | 2010-06-10 | リボバックス バイオテクノロジーズ ソシエテ アノニム | 風疹ウイルスに特異的な抗体 |
US20100291545A1 (en) | 2007-07-25 | 2010-11-18 | Takaji Wakita | Antibody having inhibitory activity on infection with hepatitis c virus (hcv) and use thereof |
TW200940090A (en) * | 2007-12-17 | 2009-10-01 | Medical Res Council Technology | Hepatitis C virus antibodies |
ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
ITTO20080398A1 (it) | 2008-05-27 | 2009-11-28 | Pomona Biotechnologies Llc | Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1 |
WO2010035292A1 (en) * | 2008-09-24 | 2010-04-01 | Natimab Therapeutics S.R.L. | The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections |
US20100104555A1 (en) * | 2008-10-24 | 2010-04-29 | The Scripps Research Institute | HCV neutralizing epitopes |
ITTO20080964A1 (it) * | 2008-12-22 | 2010-06-23 | Natimab Therapeutics S R L | Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv |
IT1395961B1 (it) | 2009-06-01 | 2012-11-02 | Pomona Biotechnologies Llc | Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv) |
US8592559B2 (en) | 2009-10-30 | 2013-11-26 | Toray Industries, Inc. | Antibody having activity of inhibiting hepatitis C virus (HCV) infection and use thereof |
AU2011223906B2 (en) | 2010-03-01 | 2015-06-25 | Vincent Agnello | Prognostic marker for cryoglobulinemic vasculitis and B cell malignancies in HCV infected patients |
CN104119436B (zh) * | 2013-04-27 | 2016-12-28 | 中国科学院上海生命科学研究院 | 抗丙型肝炎病毒的中和性全人单克隆抗体 |
GB201415714D0 (en) * | 2014-09-05 | 2014-10-22 | Medical Res Council | Antibodies and antigen binding fragments thereof |
CN105254756B (zh) * | 2015-11-27 | 2018-09-07 | 武汉大学 | 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用 |
KR20180001380U (ko) | 2016-10-31 | 2018-05-10 | 대우조선해양 주식회사 | 해양구조물의 발로 작동시키는 캡스탄 |
EP4083211A4 (en) | 2019-12-27 | 2024-07-03 | Chiome Bioscience Inc | ANTI-CDCP1 ANTIBODIES |
EP4215211A1 (en) | 2020-09-02 | 2023-07-26 | The University of Tokyo | Tumor immune microenvironment regulator, and preventive, diagnostic or therapeutic use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5285899A (en) * | 1998-07-21 | 2000-02-14 | Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh | Anti hepatitis c virus antibody and uses thereof |
US7091324B2 (en) * | 1998-11-05 | 2006-08-15 | Board Of Trustees Of Leland Stanford Junior University | Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes |
AU2001273363A1 (en) | 2000-07-12 | 2002-01-21 | General Instrument Corporation | Method and apparatus for downloading objects via an inband channel with minimal subscriber impact |
CA2429946A1 (en) * | 2000-12-01 | 2002-07-18 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services | Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c |
-
2002
- 2002-01-30 IT IT2002RM000049A patent/ITRM20020049A1/it unknown
-
2003
- 2003-01-29 RU RU2004126238/13A patent/RU2004126238A/ru not_active Application Discontinuation
- 2003-01-29 ES ES03705004T patent/ES2314179T3/es not_active Expired - Lifetime
- 2003-01-29 EP EP03705004A patent/EP1476468B9/en not_active Expired - Lifetime
- 2003-01-29 EA EA200401081A patent/EA009861B1/ru not_active IP Right Cessation
- 2003-01-29 AT AT03705004T patent/ATE407147T1/de not_active IP Right Cessation
- 2003-01-29 US US10/502,307 patent/US20050084845A1/en not_active Abandoned
- 2003-01-29 JP JP2003564093A patent/JP4287280B2/ja not_active Expired - Fee Related
- 2003-01-29 KR KR1020047011208A patent/KR101002791B1/ko active IP Right Grant
- 2003-01-29 CA CA2474801A patent/CA2474801C/en not_active Expired - Lifetime
- 2003-01-29 DK DK03705004T patent/DK1476468T3/da active
- 2003-01-29 CN CNA038030926A patent/CN1856508A/zh active Pending
- 2003-01-29 AU AU2003208000A patent/AU2003208000B2/en not_active Ceased
- 2003-01-29 DE DE60323333T patent/DE60323333D1/de not_active Expired - Lifetime
- 2003-01-29 NZ NZ534922A patent/NZ534922A/en not_active IP Right Cessation
- 2003-01-29 WO PCT/IT2003/000032 patent/WO2003064473A2/en active IP Right Grant
-
2004
- 2004-08-03 ZA ZA200406187A patent/ZA200406187B/en unknown
-
2008
- 2008-05-28 US US12/128,344 patent/US7727529B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ZA200406187B (en) | 2006-06-28 |
EP1476468A2 (en) | 2004-11-17 |
NZ534922A (en) | 2008-07-31 |
KR20040077745A (ko) | 2004-09-06 |
ATE407147T1 (de) | 2008-09-15 |
US7727529B2 (en) | 2010-06-01 |
WO2003064473A2 (en) | 2003-08-07 |
DK1476468T3 (da) | 2009-01-19 |
CA2474801C (en) | 2012-03-20 |
EP1476468B9 (en) | 2009-04-08 |
US20080241162A1 (en) | 2008-10-02 |
US20050084845A1 (en) | 2005-04-21 |
DE60323333D1 (de) | 2008-10-16 |
EA200401081A1 (ru) | 2005-10-27 |
WO2003064473A3 (en) | 2003-12-24 |
JP2005531286A (ja) | 2005-10-20 |
RU2004126238A (ru) | 2005-04-20 |
ITRM20020049A0 (it) | 2002-01-30 |
JP4287280B2 (ja) | 2009-07-01 |
CN1856508A (zh) | 2006-11-01 |
EA009861B1 (ru) | 2008-04-28 |
KR101002791B1 (ko) | 2010-12-21 |
ES2314179T3 (es) | 2009-03-16 |
AU2003208000B2 (en) | 2010-05-20 |
EP1476468B1 (en) | 2008-09-03 |
CA2474801A1 (en) | 2003-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ITRM20020049A1 (it) | Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro. | |
EA201300022A1 (ru) | Терапевтическое человеческое моноклональное антитело против il-1r1 | |
LTC1620113I2 (lt) | Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui | |
NZ527283A (en) | Modified antibodies and methods of use | |
AR069981A1 (es) | Los "anticuerpo modificado geneticamente que reconocen cd138". | |
DK1383785T3 (da) | Rekombinant tumorspecifikt antistof og anvendelse deraf | |
TR201900764T4 (tr) | LAG-3 ve terapötik antikorlar içeren bileşimler ve bunların kanser tedavisinde kullanımı. | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
DK1534335T3 (da) | FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf | |
ATE364618T1 (de) | Antikörper gegen das muc18-antigen | |
ECSP066379A (es) | Anticuerpos rg1 y usos de los mismos | |
BR0312692A (pt) | anticorpos selecionados e peptìdeos de duramicina que se ligam a fosfolipìdios aniÈnicos e aminofosfolipìdios e seus usos no tratamento de infecções virais e cáncer | |
ATE402192T1 (de) | Anti-ccr4 antikörper und fragmente davon | |
CR8108A (es) | Tratamiento con anticuerpos anti-vegf | |
TR200202253T2 (tr) | IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri | |
CR8698A (es) | Anticuerpos monoclonales al factor de crecimiento de hepatocito | |
MXPA05010830A (es) | Metodos de tratamiento que usan agentes de enlace especificos de angiopoyetina-2 humana. | |
WO2005120557A3 (en) | Inhibition of macrophage-stimulating protein receptor (ron) | |
WO2001068708A3 (en) | Human and humanized fap-alpha-specific antibodies | |
AU2001235006A1 (en) | Prophylactic and therapeutic monoclonal antibodies | |
YU55203A (sh) | Konjugati jedinjenja specifičnog makrolida imunske ćelije sa anti-inflamatornim jedinjenjima, za poboljšano ćelijsko ciljanje u anti-inflamatornoj terapiji | |
UA94211C2 (ru) | Выделенное полностью человеческое моноклональное cd3 антитело | |
WO2006137938A3 (en) | Antibody fragments for protection from pathogen infection and methods of use thereof | |
EE05474B1 (et) | Antikehade kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nhtud vhivastaseks vaktsineerimiseks | |
MY141459A (en) | Recombinant anti-idiotypic antibodies |